Key PointsQuestionWhat are the long-term responses with combined ibrutinib and venetoclax first-line therapy in patients with chronic lymphocytic leukemia? FindingsIn this phase 2 nonrandomized trial, 80 previously untreated patients with chronic lymphocytic leukemia received combined ibrutinib and venetoclax for 24 cycles; on an intent-to-treat analysis, bone marrow–undetectable measurable residual disease remission was achieved by 56% of the patients at 12 cycles and 66% of the patients at 24 cycles of combined treatment. Overall, 75% of the patients achieved bone marrow–undetectable measurable residual disease remission as best response, with 3-year progression-free survival noted in 93% of the patients. MeaningThe findings of this study suggest that combination therapy with ibrutinib and venetoclax may be a useful regimen for previously untreated patients with chronic lymphocytic leukemia.
JAMA Oncology – American Medical Association
Published: Aug 10, 2021